Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

The Prescription of Success: Improving Pipelines, Increasing Capabilities - Research Report on Globus, Akorn, Anika, Orthofix



 The Prescription of Success: Improving Pipelines, Increasing Capabilities -
  Research Report on Globus, Akorn, Anika, Orthofix and Sangamo Biosciences

PR Newswire

NEW YORK, March 5, 2013

NEW YORK, March 5, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Globus
Medical Inc (NYSE: GMED), Akorn, Inc. (NASDAQ: AKRX), Anika Therapeutics, Inc.
(NASDAQ: ANIK), Orthofix International NV (NASDAQ: OFIX) and Sangamo
Biosciences, Inc. (NASDAQ: SGMO). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Globus Medical Inc Research Report

Globus delivered a strong year with worldwide sales of $386 million, up 16.4
percent from 2011. The company was also able to increase its diluted EPS by
46.7 percent over the fourth quarter. Globus Chairman and CEO Dave Demski was
pleased with the company's revenue growth, profitability, and strong IPO and
product developments. Globus continues to invest in expanding its facilities
to drive growth. It is also expanding globally, establishing its presence in
24 countries. Because of its strong growth prospects, Piper Jaffray raised
their price target on Globus to $22. They currently maintain an Overweight
rating. The Full Research Report on Globus Medical Inc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/09f5_GMED] - Bad
link

--

Akorn, Inc. Research Report

Shares for Akorn rallied by more than 6.5 percent after the company reported
its fourth quarter earnings. Akorn's profit climbed 54 percent, as
acquisitions and newly approved products helped improve revenue. The company's
adjusted earnings of 13 cents per share beat analysts' estimates by a cent. To
continue its strong momentum, Akorn is planning to further invest in R&D while
expanding its facilities in India to build new capacities. Akorn's R&D
pipeline includes 56 abbreviated new drug applications (ANDA), with combined
annual addressable IMS market size of about $5.8 billion. The company is on
its way to file 10 additional products in the near future. The Full Research
Report on Akorn, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/60e9_AKRX]

--

Anika Therapeutics, Inc. Research Report

Anika Therapeutics gave investors a reason to celebrate after reporting fourth
quarter revenue that increased 23 percent and earnings that jumped 48 percent.
The strong growth was attributed to the strong sales for orthovisc, the
company's flagship orthiobiologics product. Orthovisc closed the year as the
market leading product. The company is also taking steps for the regulatory
approval of Monovisc. The company intends to improve its manufacturing
capabilities in order to meet the high level of demand for its products. Its
promising pipeline is also another reason to be excited. The Full Research
Report on Anika Therapeutics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investors-alliance.com/r/full_research_report/25da_ANIK]

--

Orthofix International NV Research Report

Orthofix CEO Robert Vaters purchased 3000 shares at a price of $35.97, showing
his confidence in his company's prospects. Following his purchase, shares for
Orthofix moved up by almost 3 percent. Vaters has expressed his desire to
overcome near-term challenges and improve the company's margins. A better
financial standing would allow the company to further develop its pipeline and
drive growth. In the coming year, the company expects constant currency net
sales growth from 1 to 3 percent over 2012. The Full Research Report on
Orthofix International NV - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/a593_OFIX]

--

Sangamo Biosciences, Inc. Research Report

Shares for Sangamo Biosciences rose by 9.45 percent after a Lazard Capital
Markets analyst started coverage on the company with a Buy rating and a price
target of $16 per share. The analyst noted that the company's products could
be "a big step forward for gene therapy." He also commended the company's
effort to study drugs that have limited treatment options. The company is
expecting to report data from mid-stage clinical trials for HIV and AIDS
within the year. Earlier this month, the company reported fourth quarter
revenue of $8.9 million compared to $4.7 million in the fourth quarter of
2011. The Full Research Report on Sangamo Biosciences, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4ad5_SGMO]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement